Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model

[1]  A. Pavlick,et al.  Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma , 2012, Investigational New Drugs.

[2]  G. van der Pluijm,et al.  Tumorigenesis and Neoplastic Progression Integrin v Expression Is Required for the Acquisition of a Metastatic Stem / Progenitor Cell Phenotype in Human Prostate Cancer , 2011 .

[3]  P. Fracasso,et al.  A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer , 2011, Investigational New Drugs.

[4]  D. Schadendorf,et al.  A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma , 2011, British Journal of Cancer.

[5]  J. Feyen,et al.  Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. , 2011, Neoplasia.

[6]  Wolfhard Semmler,et al.  Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE‐MRI in a longitudinal in vivo study , 2011, International journal of cancer.

[7]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[8]  S. Knox,et al.  Cancer esearch apeutics , Targets , and Chemical Biology i – α v Integrin Monoclonal Antibody Intetumumab Enhances Efficacy of Radiation Therapy and Reduces Metastasis R uman Cancer Xenografts in Nude Rats , 2010 .

[9]  P. Steeg,et al.  Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.

[10]  B. Felding-Habermann,et al.  Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain , 2009, Proceedings of the National Academy of Sciences.

[11]  A. Bandyopadhyay,et al.  Defining the Role of Integrin αvβ6 in Cancer , 2009 .

[12]  D. Tarin,et al.  Integrin αvβ3/c-src “Oncogenic Unit” Promotes Anchorage-independence and Tumor Progression , 2009, Nature Medicine.

[13]  E. Neuwelt,et al.  Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. , 2009, Neoplasia.

[14]  S. Steinberg,et al.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. , 2008, Journal of the National Cancer Institute.

[15]  S. Lockett,et al.  Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. , 2008, Cancer research.

[16]  B. Garmy-Susini,et al.  Integrins in angiogenesis and lymphangiogenesis , 2008, Nature Reviews Cancer.

[17]  T. Mikkelsen,et al.  Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiforme , 2008 .

[18]  G. Thomas,et al.  alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. , 2008, Cancer research.

[19]  E. Raymond,et al.  Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors , 2008, Investigational New Drugs.

[20]  I. Hart,et al.  Integrin trafficking and its role in cancer metastasis , 2007, Cancer and Metastasis Reviews.

[21]  G. Krissansen,et al.  Antisense integrin αV and β3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas , 2007 .

[22]  S. Steinberg,et al.  Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. , 2007, Cancer research.

[23]  Robert A. Beckman,et al.  Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[24]  V. Tse,et al.  Molecular events of brain metastasis. , 2007, Neurosurgical focus.

[25]  P. Kiener,et al.  Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™ , 2006, Molecular Cancer Therapeutics.

[26]  D. Schlaepfer,et al.  Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.

[27]  E. Neuwelt,et al.  The Chemoprotective Agent N-Acetylcysteine Blocks Cisplatin-Induced Apoptosis through Caspase Signaling Pathway , 2005, Journal of Pharmacology and Experimental Therapeutics.

[28]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[29]  M. Trikha,et al.  CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo , 2004, International journal of cancer.

[30]  N. Fedarko,et al.  Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. , 2004, Journal of the National Cancer Institute.

[31]  D. Stupack,et al.  A Bit-role for integrins in apoptosis , 2004, Nature Cell Biology.

[32]  Heather Kalish,et al.  Comparison of Transfection Agents in Forming Complexes with Ferumoxides, Cell Labeling Efficiency, and Cellular Viability , 2004, Molecular imaging.

[33]  David A. Cheresh,et al.  Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.

[34]  Hiroyuki Shimada,et al.  Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.

[35]  D. Cheresh,et al.  Role of alpha v integrins during angiogenesis. , 2000, Cancer journal.

[36]  Xin Li,et al.  Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. , 2011, Neuro-oncology.

[37]  A. Bandyopadhyay,et al.  Defining the role of integrin alphavbeta6 in cancer. , 2009, Current drug targets.

[38]  E. Raymond,et al.  Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. , 2008, Investigational new drugs.

[39]  G. Krissansen,et al.  Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[40]  F. McCabe,et al.  CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells , 2007, Clinical & Experimental Metastasis.

[41]  R. Weil,et al.  Brain metastases of breast cancer. , 2006, Breast disease.

[42]  D. Stupack,et al.  Integrins and angiogenesis. , 2004, Current topics in developmental biology.

[43]  N. Fedarko,et al.  Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. , 2004, Journal of the National Cancer Institute.

[44]  K. Arihiro,et al.  Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. , 2000, Breast cancer.

[45]  K. Arihiro,et al.  Significance of α9β1 and αvβ6 integrin expression in breast carcinoma , 2000 .